174 related articles for article (PubMed ID: 24828667)
1. Small-cell lung cancers in patients who never smoked cigarettes.
Varghese AM; Zakowski MF; Yu HA; Won HH; Riely GJ; Krug LM; Kris MG; Rekhtman N; Ladanyi M; Wang L; Berger MF; Pietanza MC
J Thorac Oncol; 2014 Jun; 9(6):892-6. PubMed ID: 24828667
[TBL] [Abstract][Full Text] [Related]
2. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.
Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB
Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486
[TBL] [Abstract][Full Text] [Related]
3. Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers.
Mc Leer A; Foll M; Brevet M; Antoine M; Novello S; Mondet J; Cadranel J; Girard N; Giaj Levra M; Demontrond P; Audigier-Valette C; Letouzé E; Lantuéjoul S; Fernandez-Cuesta L; Moro-Sibilot D
Lung Cancer; 2022 May; 167():98-106. PubMed ID: 35183375
[TBL] [Abstract][Full Text] [Related]
4. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Chaft JE; Arcila ME; Paik PK; Lau C; Riely GJ; Pietanza MC; Zakowski MF; Rusch V; Sima CS; Ladanyi M; Kris MG
Mol Cancer Ther; 2012 Feb; 11(2):485-91. PubMed ID: 22135231
[TBL] [Abstract][Full Text] [Related]
5. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Marcoux N; Gettinger SN; O'Kane G; Arbour KC; Neal JW; Husain H; Evans TL; Brahmer JR; Muzikansky A; Bonomi PD; Del Prete S; Wurtz A; Farago AF; Dias-Santagata D; Mino-Kenudson M; Reckamp KL; Yu HA; Wakelee HA; Shepherd FA; Piotrowska Z; Sequist LV
J Clin Oncol; 2019 Feb; 37(4):278-285. PubMed ID: 30550363
[TBL] [Abstract][Full Text] [Related]
6. De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.
Le X; Desai NV; Majid A; Karp RS; Huberman MS; Rangachari D; Kent MS; Gangadharan SP; Folch E; VanderLaan PA; Costa DB
Lung Cancer; 2015 Apr; 88(1):70-3. PubMed ID: 25700797
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.
Couraud S; Vaca-Paniagua F; Villar S; Oliver J; Schuster T; Blanché H; Girard N; Trédaniel J; Guilleminault L; Gervais R; Prim N; Vincent M; Margery J; Larivé S; Foucher P; Duvert B; Vallee M; Le Calvez-Kelm F; McKay J; Missy P; Morin F; Zalcman G; Olivier M; Souquet PJ;
Clin Cancer Res; 2014 Sep; 20(17):4613-24. PubMed ID: 25013125
[TBL] [Abstract][Full Text] [Related]
8. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
Dogan S; Shen R; Ang DC; Johnson ML; D'Angelo SP; Paik PK; Brzostowski EB; Riely GJ; Kris MG; Zakowski MF; Ladanyi M
Clin Cancer Res; 2012 Nov; 18(22):6169-77. PubMed ID: 23014527
[TBL] [Abstract][Full Text] [Related]
9. Personalized targeted therapy for lung cancer.
Wu K; House L; Liu W; Cho WCS
Int J Mol Sci; 2012; 13(9):11471-11496. PubMed ID: 23109866
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and prognosis of EGFR mutations in small cell lung cancer patients in the NGS era.
Xie X; Qiu G; Chen Z; Liu T; Yang Y; You Z; Zeng C; Lin X; Xie Z; Qin Y; Wang Y; Ma X; Zhou C; Liu M
Clin Transl Oncol; 2024 Feb; 26(2):434-445. PubMed ID: 37436674
[TBL] [Abstract][Full Text] [Related]
11. Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing.
Cai X; Sheng J; Tang C; Nandakumar V; Ye H; Ji H; Tang H; Qin Y; Guan H; Lou F; Zhang D; Sun H; Dong H; Zhang G; Liu Z; Dong Z; Guo B; Yan H; Yan C; Wang L; Su Z; Li Y; Jones L; Huang XF; Chen SY; Wu T; Lin H
PLoS One; 2014; 9(4):e95228. PubMed ID: 24760004
[TBL] [Abstract][Full Text] [Related]
12. Comparative genomics of high grade neuroendocrine carcinoma of the cervix.
Hillman RT; Cardnell R; Fujimoto J; Lee WC; Zhang J; Byers LA; Ramalingam P; Leitao M; Swisher E; Futreal PA; Frumovitz M
PLoS One; 2020; 15(6):e0234505. PubMed ID: 32544169
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.
Capodanno A; Boldrini L; Alì G; Pelliccioni S; Mussi A; Fontanini G
Oncol Rep; 2012 Nov; 28(5):1559-66. PubMed ID: 22949056
[TBL] [Abstract][Full Text] [Related]
14. Genotyping of RB1 status identifies two distinct subtypes in EGFR-mutant lung cancers with SCLC transformation.
Huang J; Zhang SL; Zhang C; Huang W; Zhang Z; Chen YQ; Su JW; Yan HH; Chen HJ; Yang JJ; Wang J; Wu YL
Clin Transl Med; 2024 May; 14(5):e1683. PubMed ID: 38736106
[No Abstract] [Full Text] [Related]
15. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From
Zhang B; Lewis W; Stewart CA; Morris BB; Solis LM; Serrano A; Xi Y; Wang Q; Lopez ER; Concannon K; Heeke S; Tang X; Raso G; Cardnell RJ; Vokes N; Blumenschein G; Elamin Y; Fosella F; Tsao A; Skoulidis F; Hume CB; Sasak K; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee J; Tran H; Zhang J; Gibbons D; Vaporciyan A; Wang J; Park K; Heymach JV; Byers LA; Gay CM; Le X
JTO Clin Res Rep; 2024 Feb; 5(2):100623. PubMed ID: 38357092
[TBL] [Abstract][Full Text] [Related]
16. Genomic and evolutionary classification of lung cancer in never smokers.
Zhang T; Joubert P; Ansari-Pour N; Zhao W; Hoang PH; Lokanga R; Moye AL; Rosenbaum J; Gonzalez-Perez A; Martínez-Jiménez F; Castro A; Muscarella LA; Hofman P; Consonni D; Pesatori AC; Kebede M; Li M; Gould Rothberg BE; Peneva I; Schabath MB; Poeta ML; Costantini M; Hirsch D; Heselmeyer-Haddad K; Hutchinson A; Olanich M; Lawrence SM; Lenz P; Duggan M; Bhawsar PMS; Sang J; Kim J; Mendoza L; Saini N; Klimczak LJ; Islam SMA; Otlu B; Khandekar A; Cole N; Stewart DR; Choi J; Brown KM; Caporaso NE; Wilson SH; Pommier Y; Lan Q; Rothman N; Almeida JS; Carter H; Ried T; Kim CF; Lopez-Bigas N; Garcia-Closas M; Shi J; Bossé Y; Zhu B; Gordenin DA; Alexandrov LB; Chanock SJ; Wedge DC; Landi MT
Nat Genet; 2021 Sep; 53(9):1348-1359. PubMed ID: 34493867
[TBL] [Abstract][Full Text] [Related]
17. P53 and Rb Aberrations in Small Cell Lung Cancer (SCLC): From Molecular Mechanisms to Therapeutic Modulation.
Papavassiliou KA; Sofianidi AA; Gogou VA; Anagnostopoulos N; Papavassiliou AG
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473726
[TBL] [Abstract][Full Text] [Related]
18. Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs.
Pal Choudhuri S; Girard L; Lim JYS; Wise JF; Freitas B; Yang D; Wong E; Hamilton S; Chien VD; Kim YJ; Gilbreath C; Zhong J; Phat S; Myers DT; Christensen CL; Mazloom-Farsibaf H; Stanzione M; Wong KK; Hung YP; Farago AF; Meador CB; Dyson NJ; Lawrence MS; Wu S; Drapkin BJ
Cancer Discov; 2024 May; 14(5):804-827. PubMed ID: 38386926
[TBL] [Abstract][Full Text] [Related]
19. Molecular and Genetic Advances in Small Cell Lung Cancer Landscape: From Homogeneity to Diversity.
Zullo L; Dall'Olio FG; Rossi G; Dellepiane C; Barletta G; Bennicelli E; Ingaliso M; Tagliamento M; Genova C
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203395
[TBL] [Abstract][Full Text] [Related]
20. Unleashing a Lazarus Effect With Selpercatinib in a Never-Smoker Patient With Stage IV, Chemo-Immunotherapy Refractory,
Calles A; Arregui M; Suárez-González J; García-Martos M; Márquez-Rodas I; Álvarez R; Martin M
JCO Precis Oncol; 2023 Sep; 7():e2300321. PubMed ID: 37922409
[No Abstract] [Full Text] [Related]
[Next] [New Search]
